AFM
ESPR

Anson Funds Management’s Esperion Therapeutics ESPR Stock Holding History

Anson Funds Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-327,110
Closed -$540K – 169
2024
Q3 		$540K Buy
+327,110
New +$661K 0.05% 127

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Anson Funds Management's ESPR Position: Q4 2024 in Review

Anson Funds Management sold out of Esperion Therapeutics (ESPR) in Q4 2024, closing a stake of 327,110 shares — an estimated $540K sold.

Anson Funds Management first reported a position in ESPR in Q3 2024 and held it in 1 quarter. The position peaked at $540K in Q3 2024. 189 funds tracked by Wall St. Rank hold ESPR as of Q4 2024.

  • Anson Funds Management reported no remaining Esperion Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Anson Funds Management sold 327,110 Esperion Therapeutics shares in Q4 2024, an estimated $540K.
  • Anson Funds Management first reported a position in Esperion Therapeutics in Q3 2024 and held it in 1 quarter.
  • Anson Funds Management's Esperion Therapeutics position peaked at $540K in Q3 2024.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2024.

Based on Anson Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.